ClinicalTrials.gg

Program

Extended Release Torsemide Tablets

Also written as “Extended release torsemide 24mg tablet” and “Extended release torsemide”.

Its studies are mostly in Heart Failure, led by Sarfez Pharmaceuticals.

Furthest: phase 4, since May 16, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sarfez Pharmaceuticals30 open or runningphase 4since May 16, 2025Dec 11, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2023First study: phase 2 study in Heart FailureFirst studyNCT06176794 · United States
  2. Jan 4, 2024Phase 2 study in Heart FailureNCT06206512 · 24 enrolled · United States
  3. May 16, 2025Phase 4 study in Heart FailureNCT06995144 · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06995144Heart Failure · United States4WithdrawnSep 16, 20260
NCT06206512Heart Failure · United States2CompletedNov 17, 202524
NCT06176794Heart Failure · United States2WithdrawnMar 25, 20250

How it is read

Names in the registry

  • “Extended Release Torsemide Tablets”, 1 entry
  • “Extended release torsemide 24mg tablet”, 1 entry
  • “Extended release torsemide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.